Clinical Laserthermia Systems Exhibits MRI-Guided Laser Ablation System at Southwest Prostate Cancer Symposium

SCOTTSDALE, Ariz., April 11, 2018 -- Clinical Laserthermia Systems Americas, Inc. (CLS) a subsidiary of CLS AB in Lund, Sweden, today announced it will be exhibiting its TRANBERG® Thermal Therapy System, mobile laser, and single-use products at the 23^rd Annual Southwest Prostate Cancer Symposium being held at the Fairmont Scottsdale Princess, Arizona, April 12-15, 2018.

The TRANBERG Thermal Therapy System is designed to reduce morbidity and improve clinical outcomes within interventional oncology and urology.  The system is currently in use at hospitals in the U.S. for MRI-guided focal laser ablation treatment, and included in clinical studies in Canada and Europe.

The 23rd Annual Southwest Prostate Cancer Symposium brings together world-renowned experts in the management of prostate cancer and will provide a technical update on all aspects of diagnosis and treatment of localized and advanced disease.

CLS High Precision Thermal Therapy System
The TRANBERG® |Thermal Therapy System has been developed for image guided high precision soft tissue thermal therapy and ablation procedures. The system can be configured for MR or CT/US guided procedures using tissue temperature feedback for precise therapy and ablation control. It includes a desk-top mobile laser unit, innovative non-cooled laser applicators, external tissue temperature probe sensors, and procedure specific accessories.

Laser Applicator Non-cooled
The applicator portfolio includes 3m and 12m non-cooled 16 Gauge laser applicators allowing for almost any type of image guidance, including MR. With CLS’ unique diffusing fiber technology, heat distribution in tissue is optimized and the need for external cooling is eliminated. Features also aimed at improving workflow and shortening procedure time.

About Clinical Laserthermia Systems
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System including its specially-designed sterile disposable products for safe, gentle and effective treatment of soft tissue such as cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Boston, MA, is listed on Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on www.clinicallaser.se.

The TRANBERG®|Thermal Therapy System has not yet received market clearance for immune stimulating interstitial laser thermotherapy (imILT®) by the Food and Drug Administration (FDA) in the United States of America (USA).

Media Contact
TopSpin Communications
Joe Waldygo
P: 480-363-8774
E: [email protected]

Company Contact
CLS Americas, Inc.
Alan Weinberg, General Manager 
P: (508) 620-4521
E: [email protected]